Gpc3 expression in liver cancer
WebThe protein expression data is derived from antibody-based protein profiling using immunohistochemistry. A summary of RNA categories for human tissues, cell lines and cancer tissues. Categories for RNA specificity include tissue enriched, group enriched, tissue enhanced, low tissue specificity and not detected.
Gpc3 expression in liver cancer
Did you know?
WebGPC3. GPC3 belongs to heparin sulfate proteoglycan family, can be immobilized on the cell surface by glycosylphosphatidylinositol anchors. GPC3 can be expressed in a variety of tissues during embryonic development. Beyond that life state, it is a highly tumor-specific antigen in which expression is severely inhibited in most adult tissues. WebExpression of GPC3 (DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1) in cancer tissue. The cancer tissue page shows antibody staining of the protein in 20 different cancers.
WebJan 2, 2024 · Citation 28 L02 is the normal liver cell line with GPC3-negative expression. Citation 29 GPC3 is readily accessible for antibody-mediated targeting and binding. Citation 30 Flow cytometry showed that the GPC3-expressing HepG2 cells were specifically targeted the GPC3-NPs, the GPC3-nanoparticles only localized to the cell surface of HepG2 cells ... WebSince GPC3 was revealed as a new marker of liver cancer in 1997, its biological function and expression pattern have been gradually identified, and it has evolved from a …
WebMar 31, 2024 · "GPC3 is a clinically relevant biomarker for diagnostic imaging and targeted therapeutics, as its expression is liver cancer specific and absent from normal and … WebMar 9, 2024 · In humanized liver cancer xenograft models, ... (IHC) analysis of GPC3 expression: Cohort A (GPC3 IHC 2+/3+), Cohort B (GPC3 IHC 1+) and Cohort C (GPC3 IHC 0), and were randomized in a 2:1 ratio to codrituzumab versus placebo. For this survival model analysis, 121 patients who were administered at least one dose of codrituzumab …
WebSep 10, 2024 · Primary liver cancer is the sixth most common malignant neoplasm and the second most common cause of cancer-related death worldwide . ... The expression of …
WebOct 4, 2024 · Abstract—Glypican-3 (GPC3), a heparan sulfate proteoglycan is an emerging tumor marker; its overexpression has been stated in several types of cancer such as … kaust electrical engineeringWebAug 3, 2024 · Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancer cases and is the sixth most common and the second most lethal cancer worldwide [1, 2].The majority of HCC occurs in patients with underlying chronic liver disease, mostly as a result of hepatitis B or hepatitis C virus infection and alcohol consumption [].However, … kaust directoryWebJun 10, 2024 · However, GPC3 expression was not significantly associated with these clinical phenotypes in LUSC. GPC3 overexpression in liver cancer has been frequently reported without debate; however, its expression pattern in NSCLC remains debatable. Kim et al. reported that GPC3 expression was decreased in LUAD compared with that in … kaust computer visionWebGlypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver … kaust final personal interviewWebAug 3, 2024 · Hepatocellular carcinoma (HCC) is the most common histologic subtype of liver cancer, which is the sixth most common cancer and the fourth leading cause of cancer-related death worldwide . ... GPC3 expression was evaluated using a 4-point scale: 0, no GPC3 expression; 1+, weak expression; 2+, medium expression; 3+, strong … kaust hydrogen conferenceWebDec 1, 2008 · Abstract. Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a monoclonal antibody (mAb) against the COOH-terminal part of GPC3, which induced antibody-dependent cellular cytotoxicity (ADCC). The mAb, designated GC33, exhibited marked tumor growth … kaust discovery doctoral fellowshipWebMar 31, 2024 · "GPC3 is a clinically relevant biomarker for diagnostic imaging and targeted therapeutics, as its expression is liver cancer specific and absent from normal and other pathological liver tissues." kaust government affairs